Xilio Therapeutics (Xilio Therapeutics) Debt-to-Equity : 0.34 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Xilio Therapeutics Debt-to-Equity?

Xilio Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.36 Mil. Xilio Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $8.14 Mil. Xilio Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $36.83 Mil. Xilio Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.34.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Xilio Therapeutics's Debt-to-Equity or its related term are showing as below:

XLO' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.63 Med: 0.11 Max: 0.34
Current: 0.34

During the past 5 years, the highest Debt-to-Equity Ratio of Xilio Therapeutics was 0.34. The lowest was -0.63. And the median was 0.11.

XLO's Debt-to-Equity is ranked worse than
67.61% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs XLO: 0.34

Xilio Therapeutics Debt-to-Equity Historical Data

The historical data trend for Xilio Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xilio Therapeutics Debt-to-Equity Chart

Xilio Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.63

-0.26

0.11

0.19

0.34

Xilio Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial											0.19	0.21	0.25	0.27	0.34

Competitive Comparison of Xilio Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Xilio Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xilio Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Xilio Therapeutics's Debt-to-Equity falls into.

Xilio Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Xilio Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.362	+	8.142)	/	36.827
	=	0.34

Xilio Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.362	+	8.142)	/	36.827
	=	0.34

Xilio Therapeutics (NAS:XLO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Xilio Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Xilio Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Xilio Therapeutics (Xilio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xilio Therapeutics Inc (NAS:XLO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Winter Street, Suite 300, Waltham, MA, USA, 02451

Website

https://www.xiliotx.com

Xilio Therapeutics Inc is a biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. Leveraging the GPS platform, they are building a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. The goal is to overcome the limitations of current I-O therapies by developing products with an improved therapeutic index.

Executives

Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Katarina Luptakova	officer: Chief Medical Officer	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Christopher James Frankenfield	officer: Chief Operating Officer	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Kevin M. Brennan	officer: SVP, FINANCE AND ACCOUNTING	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Edward C English	officer: Principal Accounting Officer	828 WINTER STREET, WALTHAM MA 02451
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Robert W. Ross	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Yuan Xu	director	C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Bain Capital Life Sciences Fund Ii, L.p.	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Atlas Venture Opportunity Fund I, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Sv7 Impact Medicine Fund Lp	10 percent owner	71 KINGSWAY, LONDON X0 WC2B 6ST
Bcls Ii Investo (gp), Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investco, Lp	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Investors Ii, Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Rivervest Venture Fund Iv, L.p.	10 percent owner	101 SOUTH HANLEY ROAD, SUITE 1850, ST. LOUIS MO 63105